Skip to main content
Signal Transduction and Targeted Therapy logoLink to Signal Transduction and Targeted Therapy
. 2021 Nov 8;6:385. doi: 10.1038/s41392-021-00808-9

Correction: Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn–AhR–AQP4 signaling pathway

Lisha Du 1, Zikang Xing 1, Bangbao Tao 2, Tianqi Li 1, Dan Yang 1, Weirui Li 1, Yuanting Zheng 1, Chunxiang Kuang 3, Qing Yang 1,4,
PMCID: PMC8575872  PMID: 34750349

Correction to: Signal Transduction and Targeted Therapy 10.1038/s41392-019-0103-4, published online 21 Feb 2020

In the process of collating the raw data, the authors noticed the inadvertent mistakes in Fig. 4h & 6g that need to be corrected. The correct data are provided as follows. The key findings of the article are not affected by the corrections. We apologize for the inadvertent mistakes.graphic file with name 41392_2021_808_Fig1_HTML.jpg

Fig. 4h Migration and invasion assays of U87MG cells treated with IFN-γ + 1-MT or IFN-γ + 1-MT + Kyn.

The authors mistakenly placed the wrong representative image showing the invasion ability of U87MG cells in the IFN-γ + 1-MT group. The correct version of Fig. 4h is shown above.graphic file with name 41392_2021_808_Fig2_HTML.jpg

Fig. 6g Migration and invasion assays of U87MG cells under different conditions (magnification, ×200; scale bar, 100 μm).

The authors mistakenly placed the wrong representative images showing the migration and invasion abilities of U87MG cells in the Kyn group. The correct version of Fig. 6g is shown above.


Articles from Signal Transduction and Targeted Therapy are provided here courtesy of Nature Publishing Group

RESOURCES